18F-FDG PET/CT for monitoring of treatment response in breast cancer

Stefanie Avril, Raymond F. Muzic, Donna Plecha, Bryan J. Traughber, Shaveta Vinayak, Norbert Avril

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Abstract

Changes in tumor metabolic activity have been shown to be an early indicator of treatment effectiveness for breast cancer, mainly in the neoadjuvant setting. The histopathologic response at the completion of chemotherapy has been used as the reference standard for assessment of the accuracy of 18F-FDG PET in predicting a response during systemic treatment. Although a pathologic complete response (pCR) remains an important positive prognostic factor for an individual patient, a recent metaanalysis could validate pCR as a surrogate marker for patient outcomes only in aggressive breast cancer subtypes. For establishment of the clinical application of metabolic treatment response studies, larger series of specific breast cancer subtypes-including hormone receptor-positive, human epidermal growth factor receptor 2-positive, and triple-negative breast cancers-are necessary. In addition, thresholds for relative changes in 18F-FDG uptake to distinguish between responding and nonresponding tumors need to be validated for different systemic treatment approaches, with progression-free survival and overall survival as references. A PET-based treatment stratification is applicable clinically only if valid alternative therapies are available. Of note, patients who do not achieve a pCR might still benefit from neoadjuvant therapy enabling breast-conserving surgery. In the metastatic setting, residual tumor metabolic activity after the initiation of systemic therapy is an indicator of active disease, whereas a complete resolution of metabolic activity is predictive of a successful treatment response.

Original languageEnglish (US)
Pages (from-to)34S-39S
JournalJournal of Nuclear Medicine
Volume57
DOIs
StatePublished - Feb 1 2016

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of '<sup>18</sup>F-FDG PET/CT for monitoring of treatment response in breast cancer'. Together they form a unique fingerprint.

Cite this